SAN DIEGO, July 19, 2017 /PRNewswire/ -- Medical Marijuana, Inc. (MJNA) is the first publicly traded cannabis company in the United States. Its subsidiary HempMeds® Brasil today announced that the Company's hemp cannabidiol (CBD) oil product Real Scientific Hemp Oil™ [RSHO™] has been prescribed by doctors in the country for the treatment of patients suffering from Amyotrophic Lateral Sclerosis (ALS) and Psoriasis.
This marks the first time that Brazilian doctors prescribe RSHO™ to specifically help patients suffering from the debilitating effects of either of these two diseases. This comes two years after HempMeds® Brasil became the first company to offer legal medicinal cannabis products to patients in the country.
"The Brazilian government has once again shown that the health and well-being of their people is something they are interested in sustaining by continuing to give them access to CBD hemp oil products for patients suffering from conditions with no known cure or limited treatment options," said Dr. Stuart Titus, Chief Executive Officer of Medical Marijuana, Inc. "ALS is a deliberating condition that to this day has no treatments available and Psoriasis is a vastly common condition that affects millions and we are excited about the future for CBD-based products to enter clinical trials for these two conditions."
According to the World Health Organization's Global Report on Psoriasis, the number of people worldwide with Psoriasis is increasing, with around 125 million people affected worldwide, or about 2% to 3% of the worldwide population. In Brazil alone, it is estimated that more than 2 million people have the disease and more than 7.5 million in the United States. According to Transparency Market Research, the global market for treatment of Psoriasis was worth $7.8 billion in 2015 and is projected to grow to $12.1 billion by 2024.
Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease or motor neurone disease (MND), is a specific disease that causes the death of neurons which control voluntary muscles. It is a progressive neurodegenerative disease that affects nerve cells in the brain and the spinal cord. The disease affects an estimated 30,000 in the US and over 450,000 worldwide with no known cure available to date.
About HempMeds® Brasil
HempMeds® Brasil currently has three cannabis products approved for importation into Brazil as a prescription medication for multiple conditions including; Epilepsy, Parkinson's, Chronic Pain, Psoriasis, Cancer, Alzheimer's, Diabetes, Amyotrophic Lateral Sclerosis, Multiple Sclerosis and Migraines. The company had the first-ever cannabis product allowed for import into Brazil and its products are currently subsidized by the Brazilian government, under their health care system, for all three medical indications listed above. HempMeds® Brasil is working on additional approvals for multiple indications.
About Medical Marijuana, Inc.
Our mission is to be the premier cannabis and hemp industry innovators, leveraging our team of professionals to source, evaluate and purchase value-added companies and products, while allowing them to keep their integrity and entrepreneurial spirit. We strive to create awareness within our industry, develop environmentally-friendly, economically sustainable businesses, while increasing shareholder value. For details on Medical Marijuana, Inc.'s portfolio and investment companies, visit www.medicalmarijuanainc.com.
Shareholders are also encouraged to visit the Medical Marijuana, Inc. Shop for discounted products.
FORWARD-LOOKING DISCLAIMER AND DISCLOSURES.
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties. The statements in this press release have not been evaluated by the FDA and are not intended to diagnose, treat or cure any disease. The Company does not sell or distribute any products that are in violation of the United States Controlled Substances Act. The Company does sell and distribute hemp-based products.